✦ LIBER ✦

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

✍ Scribed by Flouri, Irini; Markatseli, Theodora E.; Voulgari, Paraskevi V.; Boki, Kyriaki A.; Papadopoulos, Ioannis; Settas, Loukas; Zisopoulos, Dimitrios; Skopouli, Fotini N.; Iliopoulos, Alexios; Bertsias, George K.; Geborek, Pierre; Drosos, Alexandros A.; Boumpas, Dimitrios T.; Sidiropoulos, Prodromos

Book ID: 121283296
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 696 KB
Volume: 43
Category: Article
ISSN: 0049-0172
DOI: 10.1016/j.semarthrit.2013.07.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of drug survival rates for ad

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

✍ R. Gniadecki; K. Kragballe; T.N. Dam; L. Skov 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

A comparative effectiveness study of ada

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

✍ Greenberg, J. D.; Reed, G.; Decktor, D.; Harrold, L.; Furst, D.; Gibofsky, A.; D 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 200 KB

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods